Tourmaline Bio (TRML) Stock Price, News & Analysis

Company Overview

Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). The company was formerly known as Tourmaline Bio, LLC and changed its name to Tourmaline Bio, Inc. in September 2022. Tourmaline Bio, Inc. was founded in 2021 and is headquartered in New York, New York.

Key Stats

• Today's Range: $15.93 to $17.04
• 50-Day Range: $12.10 to $17.85
• 52-Week Range: $11.56 to $29.79
• Volume: 297,228 shs
• Average Volume: 272,550 shs
• Market Capitalization: $431.76 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $49.33
• Consensus Rating: Buy

Tourmaline Bio Stock Analysis - MarketRank™

Tourmaline Bio scored higher than 37% of companies evaluated by MarketBeat, and ranked 739th out of 934 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Tourmaline Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Tourmaline Bio has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Tourmaline Bio are expected to decrease in the coming year, from ($3.02) to ($3.56) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Tourmaline Bio is -5.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Tourmaline Bio is -5.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Tourmaline Bio has a P/B Ratio of 1.67. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

19.91% of the float of Tourmaline Bio has been sold short.

Short Interest Ratio / Days to Cover

Tourmaline Bio has a short interest ratio ("days to cover") of 9.4.

Change versus previous month

Short interest in Tourmaline Bio has recently increased by 2.19%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Tourmaline Bio does not currently pay a dividend.

Dividend Growth

Tourmaline Bio does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

19.91% of the float of Tourmaline Bio has been sold short.

Short Interest Ratio / Days to Cover

Tourmaline Bio has a short interest ratio ("days to cover") of 9.4.

Change versus previous month

Short interest in Tourmaline Bio has recently increased by 2.19%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: 0.40

News Sentiment

Tourmaline Bio has a news sentiment score of 0.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.87 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 12 news articles for Tourmaline Bio this week, compared to 3 articles on an average week.

MarketBeat Follows

1 people have added Tourmaline Bio to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Tourmaline Bio insiders have not sold or bought any company stock.

Percentage Held by Insiders

11.02% of the stock of Tourmaline Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

91.89% of the stock of Tourmaline Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

TRML Stock Analysis - Frequently Asked Questions

How have TRML shares performed this year?

Tourmaline Bio's stock was trading at $20.28 on January 1st, 2025. Since then, TRML stock has decreased by 17.1% and is now trading at $16.81.
View the best growth stocks for 2025 here.

How were Tourmaline Bio's earnings last quarter?

Tourmaline Bio, Inc. (NASDAQ:TRML) posted its earnings results on Friday, May, 2nd. The company reported ($0.89) EPS for the quarter, beating analysts' consensus estimates of ($0.91) by $0.02.

Who are Tourmaline Bio's major shareholders?

Tourmaline Bio's top institutional shareholders include QVT Financial LP (5.74%), Vanguard Group Inc. (4.64%), Octagon Capital Advisors LP (3.52%) and Nantahala Capital Management LLC (2.07%). Insiders that own company stock include Mark Mcdade, Parvinder Thiara and Sandeep Chidambar Kulkarni.
View institutional ownership trends.

How do I buy shares of Tourmaline Bio?

Shares of TRML stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Tourmaline Bio own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Tourmaline Bio investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), TotalEnergies (TTE) and Southern First Bancshares (SFST).

Company Calendar

• Last Earnings: 5/02/2025
• Today: 5/30/2025
• Next Earnings (Estimated): 8/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:TRML
• Previous Symbol: NASDAQ:TRML
• CIK: 1827506
• Web: N/A
• Phone: 502-398-9250
• Fax: N/A
• Employees: 44
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $49.33
• High Stock Price Target: $70.00
• Low Stock Price Target: $25.00
• Potential Upside/Downside: +193.5%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 7 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($3.21)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$42.12 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -20.97%
• Return on Assets: -20.56%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 40.33
• Quick Ratio: 40.33

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $10.08 per share
• Price / Book: 1.67

Miscellaneous

• Outstanding Shares: 25,685,000
• Free Float: 22,817,000
• Market Cap: $431.76 million
• Optionable: Optionable
• Beta: 2.11